Latest Biotech News

Revolution Medicines started shipping daraxonrasib to physicians and patients under an FDA-authorized early access program for pancreatic cancer. CEO Mark Goldsmith told STAT the company is now...

Pfizer and Innovent Biologics announced a collaboration valued at up to $10.5 billion, covering a portfolio of 12 early-stage and de novo antibody-drug conjugates and multispecific oncology...

Allogene Therapeutics said Zachary Roberts will succeed David Chang as president and CEO on July 1. Roberts will also join the board and currently serves as EVP of R&D and CMO at the off-the-shelf...

Legend Biotech founder Frank Fan is returning to ASCO with a new CAR-T platform plan aimed at high-yield manufacturing and non-gene-editing approaches, according to reporting on his new ambition....

Bristol Myers Squibb presented Phase 3 results for mezigdomide in the SUCCESSOR-2 study in relapsed or refractory multiple myeloma. In the trial, adding mezigdomide to carfilzomib and...

Giredestrant showed invasive disease-free survival benefits across menopausal status in lidERA, a randomized trial in high-risk stage I–III ER+/HER2− early breast cancer. The study compared...

Puxitatug samrotecan, a B7-H4-directed antibody-drug conjugate, produced high response rates in B7-H4-expressing recurrent or progressive endometrial cancer in the BLUESTAR phase 1/2a trial. At...

Tempus AI received FDA approval for a tumor-only indication for its xT CDx next-generation sequencing platform, expanding how clinicians can profile solid tumors with comprehensive genomic...

Revolution Medicines began shipping daraxonrasib to physicians and patients under an FDA-authorized early access program for advanced pancreatic cancer, with the drug still unapproved. The step...

New interim and subgroup results from the lidERA Phase 3 trial show giredestrant reduced invasive disease or death versus standard-of-care endocrine therapy across both premenopausal and...

Puxitatug samrotecan (AZD8205) generated high response rates in B7-H4–selected recurrent or progressive endometrial cancer in the BLUESTAR Phase 1/2a program, including a 47.1% confirmed objective...

Bristol Myers Squibb unveiled Phase 3 results for mezigdomide plus carfilzomib and dexamethasone (MeziKd) in relapsed or refractory multiple myeloma under its SUCCESSOR-2 program. The mezigdomide...

Pfizer reported detailed Phase 3 TALAPRO-3 results showing talazoparib (TALZENNA) plus enzalutamide (XTANDI) improved radiographic progression-free survival in HRR gene–altered metastatic...

ASCO said it will not recommend Grail’s Galleri test for population screening after the NHS-Galleri trial failed to meet its primary endpoint. The decision comes as the controversy continues over...

A SWOG prospective cohort study reported interim results on microRNA-371a-3p (miR371) as a relapse predictor in early-stage testicular cancer patients managed with active surveillance. The...

The White House is reviewing a new FDA user fee deal that would set prescription drug user fees for 2028 through 2032, according to sources cited in the report. The development adds another...

Pfizer struck a major oncology licensing collaboration with China’s Innovent Biologics covering 12 antibody-drug conjugates and multispecific programs, including eight Innovent early-stage assets...

Allogene Therapeutics announced that its chief medical officer, Zachary Roberts, will succeed David Chang as president and CEO on July 1, with Roberts joining the board while Chang remains on the...

FDA approval for a tumor-only next-generation sequencing approach for solid tumors marks a practical shift in how comprehensive genomic profiling can be deployed in routine care. Tempus AI said...

Pfizer and Innovent Biologics escalated their global oncology collaboration with a deal sized up to $10.5 billion, anchoring the partnership around next-generation antibody-drug conjugates and...